TP53 and cancer: P53‐null or some mutant cancers may be more sensitive to the combo of metformin and hypoglycemia than those with a wild‐type p53 since the latter may be activated by both AMPK and GSK3β and attempt a metabolic compensation by fostering OXPHOS.